Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 2
1982 1
1983 10
1984 13
1985 14
1986 11
1987 13
1988 23
1989 31
1990 32
1991 30
1992 14
1993 33
1994 24
1995 32
1996 18
1997 20
1998 16
1999 15
2000 24
2001 21
2002 24
2003 23
2004 19
2005 18
2006 11
2007 23
2008 29
2009 15
2010 19
2011 14
2012 13
2013 15
2014 19
2015 14
2016 21
2017 19
2018 14
2019 20
2020 24
2021 20
2022 18
2023 17
2024 30
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

805 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial.
Dahyot-Fizelier C, Lasocki S, Kerforne T, Perrigault PF, Geeraerts T, Asehnoune K, Cinotti R, Launey Y, Cottenceau V, Laffon M, Gaillard T, Boisson M, Aleyrat C, Frasca D, Mimoz O; PROPHY-VAP Study Group and the ATLANREA Study Group. Dahyot-Fizelier C, et al. Lancet Respir Med. 2024 May;12(5):375-385. doi: 10.1016/S2213-2600(23)00471-X. Epub 2024 Jan 20. Lancet Respir Med. 2024. PMID: 38262428 Clinical Trial.
The incidence of early VAP was lower in the ceftriaxone group than in the placebo group (23 [14%] vs 51 [32%]; hazard ratio 0.60 [95% CI 0.38-0.95], p=0.030), with no microbiological impact and no adverse effects attributable to ceftriaxone. INTERPRETATION: In patie …
The incidence of early VAP was lower in the ceftriaxone group than in the placebo group (23 [14%] vs 51 [32%]; hazard ratio 0.60 [95% …
Efficacy of Ceftriaxone 1 g daily Versus 2 g daily for The Treatment of Community-Acquired Pneumonia: A Systematic Review with Meta-Analysis.
Telles JP, Cieslinski J, Gasparetto J, Tuon FF. Telles JP, et al. Expert Rev Anti Infect Ther. 2019 Jul;17(7):501-510. doi: 10.1080/14787210.2019.1627872. Epub 2019 Jun 10. Expert Rev Anti Infect Ther. 2019. PMID: 31179786
To compare ceftriaxone 1 g daily efficacy to other ceftriaxone dosing regimens in community-acquired pneumonia. ...Twenty-four articles fulfilled the inclusion criteria. Twelve studies evaluated ceftriaxone regimens at a dosage of 2 g daily and 12 studies eva …
To compare ceftriaxone 1 g daily efficacy to other ceftriaxone dosing regimens in community-acquired pneumonia. ...Twenty-four …
A Randomized Controlled Trial of Ceftriaxone and Doxycycline, With or Without Metronidazole, for the Treatment of Acute Pelvic Inflammatory Disease.
Wiesenfeld HC, Meyn LA, Darville T, Macio IS, Hillier SL. Wiesenfeld HC, et al. Clin Infect Dis. 2021 Apr 8;72(7):1181-1189. doi: 10.1093/cid/ciaa101. Clin Infect Dis. 2021. PMID: 32052831 Free PMC article. Clinical Trial.
CONCLUSIONS: In women treated for acute PID, the addition of metronidazole to ceftriaxone and doxycycline was well tolerated and resulted in reduced endometrial anaerobes, decreased M. genitalium, and reduced pelvic tenderness compared to ceftriaxone and doxycycline …
CONCLUSIONS: In women treated for acute PID, the addition of metronidazole to ceftriaxone and doxycycline was well tolerated and resu …
Response-Guided Therapy With Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Randomized Trial: A Validation Study of 2021 AASLD Practice Guidance for SBP.
Yim HJ, Kim TH, Suh SJ, Yim SY, Jung YK, Seo YS, Kang SH, Kim MY, Baik SK, Kim HS, Kim YS, Park SY, Kim BI, Park JY, Heo J, Sohn JH, Heo NY, Han KH, Um SH. Yim HJ, et al. Am J Gastroenterol. 2023 Apr 1;118(4):654-663. doi: 10.14309/ajg.0000000000002126. Epub 2023 Jan 3. Am J Gastroenterol. 2023. PMID: 36594820 Clinical Trial.
This study aimed to compare the current efficacy of the 3 antibiotics, namely cefotaxime, ceftriaxone, and ciprofloxacin, for the treatment of SBP in patients with cirrhosis with ascites, when guided by therapeutic responses. ...The resolution rates at 120 hours, which is …
This study aimed to compare the current efficacy of the 3 antibiotics, namely cefotaxime, ceftriaxone, and ciprofloxacin, for the tre …
Ceftriaxone versus antistaphylococcal antibiotics for definitive treatment of methicillin-susceptible Staphylococcus aureus infections: a systematic review and meta-analysis.
Yetmar ZA, Razi S, Nayfeh T, Gerberi DJ, Mahmood M, Abu Saleh OM. Yetmar ZA, et al. Int J Antimicrob Agents. 2022 Jan;59(1):106486. doi: 10.1016/j.ijantimicag.2021.106486. Epub 2021 Nov 26. Int J Antimicrob Agents. 2022. PMID: 34839007
Definitive therapy with ceftriaxone was associated with a lower risk of toxicity requiring therapy alteration (RR 0.49, 95% CI 0.27-0.88; I(2) = 0%). ...Current evidence suggests there is no difference in efficacy between ceftriaxone and ASAs for MSSA infection, wit …
Definitive therapy with ceftriaxone was associated with a lower risk of toxicity requiring therapy alteration (RR 0.49, 95% CI 0.27-0 …
Inappropriate ceftriaxone utilization and predictor factors in Ethiopia: a systematic review and meta-analysis.
Tafere C, Endeshaw D, Demsie DG, Yismaw MB, Tefera BB, Yehualaw A, Feyisa K, Siraj EA, Yayehrad AT, Addisu ZD, Adal O. Tafere C, et al. Sci Rep. 2024 Oct 23;14(1):25035. doi: 10.1038/s41598-024-75728-z. Sci Rep. 2024. PMID: 39443593 Free PMC article.
Ceftriaxone stands as a cornerstone in global antibiotic therapy owing to its potent antibacterial activity, broad spectrum coverage, and low toxicity. ...The study reveals a high national pooled prevalence of inappropriate ceftriaxone utilization, standing at 55.24 …
Ceftriaxone stands as a cornerstone in global antibiotic therapy owing to its potent antibacterial activity, broad spectrum coverage, …
Clinical cure with ceftriaxone versus ceftaroline or ceftobiprole in the treatment of staphylococcal pneumonia: a systematic review and meta-analysis.
Eljaaly K, Wali H, Basilim A, Alharbi A, Asfour HZ. Eljaaly K, et al. Int J Antimicrob Agents. 2019 Aug;54(2):149-153. doi: 10.1016/j.ijantimicag.2019.05.023. Epub 2019 Jun 4. Int J Antimicrob Agents. 2019. PMID: 31173864
A systematic review and meta-analysis of randomised controlled trials (RCTs) comparing clinical cure in patients with pneumonia who received ceftriaxone versus those who received either ceftaroline or ceftobiprole was conducted. Patients who received ceftriaxone plu …
A systematic review and meta-analysis of randomised controlled trials (RCTs) comparing clinical cure in patients with pneumonia who received …
Safety of Single-Dose Oral Cefixime, Intramuscular Ceftriaxone, or Intramuscular Gentamicin for the Treatment of Gonorrhea: A Systematic Review and Meta-analysis.
Dresser J, Wilby KJ. Dresser J, et al. Ann Pharmacother. 2021 Jul;55(7):914-920. doi: 10.1177/1060028020966333. Epub 2020 Oct 10. Ann Pharmacother. 2021. PMID: 33043676
Two randomized controlled trials compared ceftriaxone and gentamicin. Four randomized controlled trials compared cefixime and ceftriaxone. No differences were noted for the occurrence of at least 1 adverse effect between gentamicin and ceftriaxone (odds ratio …
Two randomized controlled trials compared ceftriaxone and gentamicin. Four randomized controlled trials compared cefixime and ceft …
Efficacy and safety of ceftriaxone for uncomplicated gonorrhoea: a meta-analysis of randomized controlled trials.
Bai ZG, Bao XJ, Cheng WD, Yang KH, Li YP. Bai ZG, et al. Int J STD AIDS. 2012 Feb;23(2):126-32. doi: 10.1258/ijsa.2009.009198. Int J STD AIDS. 2012. PMID: 22422688 Review.
Cure rates of ceftriaxone 250 mg were significantly better than cefixime 400 mg (OR 1.77; 95% CI 1.11-2.80) as was ceftriaxone 125 mg versus spectinomycin 2 g (OR 3.44; 95% CI 1.08-10.90). ...In conclusion, this meta-analysis revealed that 250 mg ceftriaxone …
Cure rates of ceftriaxone 250 mg were significantly better than cefixime 400 mg (OR 1.77; 95% CI 1.11-2.80) as was ceftriaxone …
Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials.
Taboada M, Melnick D, Iaconis JP, Sun F, Zhong NS, File TM, Llorens L, Friedland HD, Wilson D. Taboada M, et al. J Antimicrob Chemother. 2016 Apr;71(4):862-70. doi: 10.1093/jac/dkv415. Epub 2015 Dec 24. J Antimicrob Chemother. 2016. PMID: 26702925 Review.

RESULTS: Clinical cure rates in each trial consistently favoured ceftaroline fosamil versus ceftriaxone, with no evidence of heterogeneity. In the meta-analysis, ceftaroline fosamil was superior to ceftriaxone in the MITT (OR: 1.66; 95% CI 1.34, 2.06; P < 0.001)

…
RESULTS: Clinical cure rates in each trial consistently favoured ceftaroline fosamil versus ceftriaxone, with no evidence of heteroge …
805 results

Searches related to "ceftriaxone"